Outcome of different modalities of management of hepatocellular carcinoma : Surgical resection and interventional radiology [TACE] /
اق ا ج سرطان ا : الاستئصال الجراحى و الأشعة التداخلية
Mohamed Khaled Mokhtar Abouelazayem ; Supervised Amr Abdelmeguid Attia , Ikram Hamed Mahmoud , Heba Gamal Eldin
- Cairo : Mohamed Khaled Mokhtar Abouelazayem , 2017
- 93 P. : facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Surgical
Background aims: HCC is an aggressive malignancy and has multiple treatment options, usually a multimodality therapy is used. The choice treatment depends on many factors including staging of tumor, patient characteristics and liver functions. This study aimed to provide a descriptive analysis of patients diagnosed with HCC in NCI and to evaluate the outcome of treatment by surgical resection and interventional radiology. Methods: The study included 84 patients of both sexes diagnosed with HCC in NCI and were retrospectively reviewed for patients characteristics, mode of presentation, investigations done, staging and treatment received. Treatment outcome was compared between the two groups regarding the local control and survival. Reuslts: Mean age was found to be 56.1 and 58.3 in SR group and IR group respectively. HCV was positive in 88% of the patients. 41 patients (48.8%) were child class A, 35 patients (41.7%) were child class B and 8 patients (9.5%) were class C. Median follow up time was 15.21 months. Recurrence rate was (42.2%) in the SR group compared to (58.9%) patients in the IR group. The 1-, 3- and 5-year overall survival for the SR group was 79%, 54% and 28% respectively while it was 55%, 11% and 5% for the IR group respectively. Conclusion: Surgical treatment remains the only curative therapy for HCC, with lower recurrence rates and longer survival. However, other modalities be used in conjunction with surgery or as a bridge to liver transplantation. Further studies are required in NCI to develop the optimum therapy or combination of therapies for HCC
Hepatocellular carcinoma Radiofrequency ablation Surgery